Signet Announces Availability of Two Monoclonal Antibodies
Product News Mar 20, 2006
Signet Laboratories, Inc. has announced the availability of two monoclonal antibodies, EGFR, clone F4 and VEGF, clone VG-1.
EGFR, clone F4, has been implicated in the development and progression of a number of human solid tumors including lung, breast, prostate, colon, ovary, head, and neck.
VEGF, clone VG-1, is a secreted glycoprotein that is a potent and specific mitogen for vascular endothelial cells that stimulates angiogenesis during embryonic development and tumor formation.
Signet's EGFR and VEGF antibodies are designed to offer researchers a valuable tool for cancer research.
These antibodies complement Signet's current product portfolio which includes markers such as D2-40, Cyclin D1, Cyclin E, HE4, and Hepsin.